vs
Side-by-side financial comparison of Infobird Co., Ltd (IFBD) and NovaBay Pharmaceuticals, Inc. (NBY). Click either name above to swap in a different company.
NovaBay Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($4.8M vs $3.4M, roughly 1.4× Infobird Co., Ltd). NovaBay Pharmaceuticals, Inc. runs the higher net margin — -25.5% vs -46.7%, a 21.2% gap on every dollar of revenue. On growth, Infobird Co., Ltd posted the faster year-over-year revenue change (17118.0% vs 126.1%).
Infobird Co., Ltd. is a China-based technology firm specializing in AI-powered customer engagement and smart customer service solutions. It serves clients across e-commerce, finance, telecommunications, and internet service sectors, offering cloud-based SaaS tools, intelligent call center systems, and customized digital operation support to help enterprises boost service efficiency and customer satisfaction.
NovaBay Pharmaceuticals, Inc. is an Emeryville, California based clinical-stage biopharmaceutical company, focused on products for eye care. Major products include Avenova, cleared by FDA for lid and lash cleansing as part of a regimen for Blepharitis. and NeutroPhase, used in treatment of Necrotizing Fasciitis
IFBD vs NBY — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2024
| Metric | | |
|---|---|---|
| Revenue | $3.4M | $4.8M |
| Net Profit | $-1.6M | $-1.2M |
| Gross Margin | 37.2% | 65.2% |
| Operating Margin | -31.8% | -37.2% |
| Net Margin | -46.7% | -25.5% |
| Revenue YoY | 17118.0% | 126.1% |
| Net Profit YoY | -98.1% | 70.5% |
| EPS (diluted) | $-0.41 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | $3.4M | — | ||
| Q4 24 | — | $4.8M | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $2.4M | ||
| Q1 24 | — | $2.6M | ||
| Q4 23 | — | $2.1M | ||
| Q3 23 | — | $2.5M | ||
| Q2 23 | — | $3.5M |
| Q2 25 | $-1.6M | — | ||
| Q4 24 | — | $-1.2M | ||
| Q3 24 | — | $-1.2M | ||
| Q2 24 | — | $-1.6M | ||
| Q1 24 | — | $-3.2M | ||
| Q4 23 | — | $-4.1M | ||
| Q3 23 | — | $-1.8M | ||
| Q2 23 | — | $-2.0M |
| Q2 25 | 37.2% | — | ||
| Q4 24 | — | 65.2% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 66.3% | ||
| Q1 24 | — | 68.2% | ||
| Q4 23 | — | 51.5% | ||
| Q3 23 | — | 67.0% | ||
| Q2 23 | — | 49.2% |
| Q2 25 | -31.8% | — | ||
| Q4 24 | — | -37.2% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -67.4% | ||
| Q1 24 | — | -87.1% | ||
| Q4 23 | — | -48.0% | ||
| Q3 23 | — | -28.1% | ||
| Q2 23 | — | -29.7% |
| Q2 25 | -46.7% | — | ||
| Q4 24 | — | -25.5% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -66.0% | ||
| Q1 24 | — | -122.2% | ||
| Q4 23 | — | -195.5% | ||
| Q3 23 | — | -70.8% | ||
| Q2 23 | — | -57.6% |
| Q2 25 | $-0.41 | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-1.92 | ||
| Q2 24 | — | $-1.37 | ||
| Q1 24 | — | $-29.95 | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $698.0K | $430.0K |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $66.7M | $-129.0K |
| Total Assets | $72.4M | $3.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $698.0K | — | ||
| Q4 24 | — | $430.0K | ||
| Q3 24 | — | $776.0K | ||
| Q2 24 | — | $751.0K | ||
| Q1 24 | — | $1.8M | ||
| Q4 23 | — | $2.9M | ||
| Q3 23 | — | $3.5M | ||
| Q2 23 | — | $4.4M |
| Q2 25 | $66.7M | — | ||
| Q4 24 | — | $-129.0K | ||
| Q3 24 | — | $1.1M | ||
| Q2 24 | — | $-617.0K | ||
| Q1 24 | — | $160.0K | ||
| Q4 23 | — | $3.3M | ||
| Q3 23 | — | $7.0M | ||
| Q2 23 | — | $8.6M |
| Q2 25 | $72.4M | — | ||
| Q4 24 | — | $3.4M | ||
| Q3 24 | — | $3.9M | ||
| Q2 24 | — | $3.9M | ||
| Q1 24 | — | $5.4M | ||
| Q4 23 | — | $9.0M | ||
| Q3 23 | — | $12.9M | ||
| Q2 23 | — | $16.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.1M | $-1.7M |
| Free Cash FlowOCF − Capex | — | $-1.7M |
| FCF MarginFCF / Revenue | — | -35.4% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $1.1M | — | ||
| Q4 24 | — | $-1.7M | ||
| Q3 24 | — | $-2.4M | ||
| Q2 24 | — | $-1.4M | ||
| Q1 24 | — | $-2.0M | ||
| Q4 23 | — | $-592.0K | ||
| Q3 23 | — | $-646.0K | ||
| Q2 23 | — | $-1.7M |
| Q2 25 | — | — | ||
| Q4 24 | — | $-1.7M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $-2.0M | ||
| Q4 23 | — | $-595.0K | ||
| Q3 23 | — | $-647.0K | ||
| Q2 23 | — | $-1.7M |
| Q2 25 | — | — | ||
| Q4 24 | — | -35.4% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -75.3% | ||
| Q4 23 | — | -28.3% | ||
| Q3 23 | — | -26.1% | ||
| Q2 23 | — | -48.3% |
| Q2 25 | — | — | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.1% | ||
| Q4 23 | — | 0.1% | ||
| Q3 23 | — | 0.0% | ||
| Q2 23 | — | 0.1% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IFBD
Segment breakdown not available.
NBY
| Other | $2.4M | 51% |
| Total Product Revenue | $2.3M | 49% |
